MacroGenics stock fell 2.47 percent on October 7 with pipeline data ahead

Published on 10/08/2026 at 00:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MacroGenics stock closed at USD 3.55 on October 7, 2026, with market capitalization at USD 225.6 million. Q2 revenue rose to USD 32.8 million.

MGNX, US5560991094, Illustration mit AI erstellt.

MacroGenics stock (ISIN US5560991094) closed at USD 3.55 on October 7, 2026, down 2.47 percent from the prior close of USD 3.64. The move leaves the clinical-stage biotechnology company valued at USD 225.6 million and puts the latest trading level 30.1 percent below its 52-week high of USD 5.08.

Q2 revenue rose 58 percent

MacroGenics reported Q2 2026 revenue of USD 32.8 million, up 58 percent from USD 20.8 million in Q1 2026, according to TheDesperateTrader. The same report lists USD 113.9 million of cash on hand at June 30, 2026, giving the balance sheet greater weight in the investment case than the quarter's revenue alone.

The revenue comparison is positive, but the company remains in development mode. MacroGenics is building antibody-drug conjugates, bispecific checkpoint antibodies and next-generation T-cell engagers, according to its investor-relations description at MacroGenics.

Analysts see upside to USD 8

MarketScreener lists an Outperform consensus from 7 analysts and an average price target of USD 8.00. That target lies 125.4 percent above the October 7 closing price of USD 3.55, according to MarketScreener. The gap reflects expectations for pipeline progress rather than a completed earnings recovery.

The next visible clinical checkpoint is October 23, 2026, when MacroGenics plans to present preliminary data for MGC026 and lorigerlimab at the European Society for Medical Oncology Congress, as reported by Simply Wall St. For investors, that date provides a concrete test of whether the pipeline can support the valuation assigned by the analyst consensus.

Stock remains below yearly high

MacroGenics stock traded on Nasdaq with a 52-week range of USD 1.29 to USD 5.08 as of October 7, 2026. Volume was 508,832 shares during the session, while the closing price remained 30.1 percent below the yearly high.